KRAS mutational testing in the selection of patients for EGFR-targeted therapies Journal Article
| Authors: | Garcia, J.; Riely, G. J.; Nafa, K.; Ladanyi, M. |
| Article Title: | KRAS mutational testing in the selection of patients for EGFR-targeted therapies |
| Abstract: | The small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and the anti-EGFR monoclonal antibodies have proven activity in lung and colorectal adenocarcinomas, respectively, but only a small fraction of patients exhibit significant responses. The observation that only a minority of patients respond to EGFR-targeted therapies, in combination with their toxicity and high costs, has driven the search for molecular markers predictive of response. The main focus of the present review is the recent discovery that mutations in the KRAS oncogene constitute a negative predictive marker in this clinical setting, namely that their presence can be used to predict which patients are unlikely to benefit from treatment with EGFR-directed therapy. © 2008 Elsevier Inc. All rights reserved. |
| Keywords: | immunohistochemistry; cancer chemotherapy; cancer survival; treatment outcome; treatment response; gene mutation; mutation; proto-oncogene proteins; clinical feature; clinical trial; erlotinib; fluorouracil; placebo; advanced cancer; drug safety; monotherapy; patient selection; skin toxicity; treatment duration; antineoplastic agents; clinical trials as topic; disease free survival; colorectal cancer; adenocarcinoma; epidermal growth factor receptor; lung cancer; combination chemotherapy; receptor, epidermal growth factor; drug resistance, neoplasm; mutational analysis; cetuximab; prediction; irinotecan; monoclonal antibody; panitumumab; protein tyrosine kinase inhibitor; protein kinase inhibitors; molecular marker; gene number; lung adenocarcinoma; fluorescence in situ hybridization; colon cancer; drug response; gefitinib; asparaginase; lung alveolus cell carcinoma; pharmacogenetics; ras proteins; oncogene k ras; lung carcinogenesis; oxaliplatin; rectum carcinoma; colon adenocarcinoma; receptor gene; cost; epidermal growth factor receptor antibody; marker gene; amphiregulin; epidermal growth factor receptor kinase inhibitor; epiregulin; kinase; gefinitib; panitimumab; small molecule transport agent |
| Journal Title: | Seminars in Diagnostic Pathology |
| Volume: | 25 |
| Issue: | 4 |
| ISSN: | 0740-2570 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2008-11-01 |
| Start Page: | 288 |
| End Page: | 294 |
| Language: | English |
| DOI: | 10.1053/j.semdp.2008.08.003 |
| PUBMED: | 19013894 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 5" - "Export Date: 17 November 2011" - "CODEN: SDPAE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work